730 related articles for article (PubMed ID: 25802333)
21. Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias.
Tobin LA; Robert C; Rapoport AP; Gojo I; Baer MR; Tomkinson AE; Rassool FV
Oncogene; 2013 Apr; 32(14):1784-93. PubMed ID: 22641215
[TBL] [Abstract][Full Text] [Related]
22. Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro.
Balabanov S; Gontarewicz A; Keller G; Raddrizzani L; Braig M; Bosotti R; Moll J; Jost E; Barett C; Rohe I; Bokemeyer C; Holyoake TL; Brümmendorf TH
PLoS One; 2011 Apr; 6(4):e19164. PubMed ID: 21541334
[TBL] [Abstract][Full Text] [Related]
23. Heme oxygenase-1 contributes to imatinib resistance by promoting autophagy in chronic myeloid leukemia through disrupting the mTOR signaling pathway.
Cao L; Wang J; Ma D; Wang P; Zhang Y; Fang Q
Biomed Pharmacother; 2016 Mar; 78():30-38. PubMed ID: 26898422
[TBL] [Abstract][Full Text] [Related]
24. The role of heterogeneous nuclear ribonucleoprotein K in the progression of chronic myeloid leukemia.
Du Q; Wang L; Zhu H; Zhang S; Xu L; Zheng W; Liu X
Med Oncol; 2010 Sep; 27(3):673-9. PubMed ID: 19653139
[TBL] [Abstract][Full Text] [Related]
25. Aberrant signalling by protein kinase CK2 in imatinib-resistant chronic myeloid leukaemia cells: biochemical evidence and therapeutic perspectives.
Borgo C; Cesaro L; Salizzato V; Ruzzene M; Massimino ML; Pinna LA; Donella-Deana A
Mol Oncol; 2013 Dec; 7(6):1103-15. PubMed ID: 24012109
[TBL] [Abstract][Full Text] [Related]
26. Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells.
Liao HF; Su YC; Zheng ZY; Jhih Cai C; Hou MH; Chao KS; Chen YJ
Biomed Pharmacother; 2012 Jul; 66(5):378-83. PubMed ID: 22397755
[TBL] [Abstract][Full Text] [Related]
27. Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds.
Aichberger KJ; Mayerhofer M; Krauth MT; Vales A; Kondo R; Derdak S; Pickl WF; Selzer E; Deininger M; Druker BJ; Sillaber C; Esterbauer H; Valent P
Cancer Res; 2005 Oct; 65(20):9436-44. PubMed ID: 16230407
[TBL] [Abstract][Full Text] [Related]
28. Suppression of survivin induced by a BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs.
Stella S; Tirrò E; Conte E; Stagno F; Di Raimondo F; Manzella L; Vigneri P
Mol Cancer Ther; 2013 Jun; 12(6):1085-98. PubMed ID: 23536723
[TBL] [Abstract][Full Text] [Related]
29. Tetrandrine citrate eliminates imatinib-resistant chronic myeloid leukemia cells in vitro and in vivo by inhibiting Bcr-Abl/β-catenin axis.
Xu XH; Gan YC; Xu GB; Chen T; Zhou H; Tang JF; Gu Y; Xu F; Xie YY; Zhao XY; Xu RZ
J Zhejiang Univ Sci B; 2012 Nov; 13(11):867-74. PubMed ID: 23125079
[TBL] [Abstract][Full Text] [Related]
30. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
Gleixner KV; Ferenc V; Peter B; Gruze A; Meyer RA; Hadzijusufovic E; Cerny-Reiterer S; Mayerhofer M; Pickl WF; Sillaber C; Valent P
Cancer Res; 2010 Feb; 70(4):1513-23. PubMed ID: 20145140
[TBL] [Abstract][Full Text] [Related]
31. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
He B; Wang Q; Liu X; Lu Z; Han J; Pan C; Carter BZ; Liu Q; Xu N; Zhou H
Biomed Pharmacother; 2020 Sep; 129():110390. PubMed ID: 32563150
[TBL] [Abstract][Full Text] [Related]
32. SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells.
Bu Q; Cui L; Li J; Du X; Zou W; Ding K; Pan J
Cancer Biol Ther; 2014 Jul; 15(7):951-62. PubMed ID: 24759597
[TBL] [Abstract][Full Text] [Related]
33. Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex.
Chen M; Gallipoli P; DeGeer D; Sloma I; Forrest DL; Chan M; Lai D; Jorgensen H; Ringrose A; Wang HM; Lambie K; Nakamoto H; Saw KM; Turhan A; Arlinghaus R; Paul J; Stobo J; Barnett MJ; Eaves A; Eaves CJ; Holyoake TL; Jiang X
J Natl Cancer Inst; 2013 Mar; 105(6):405-23. PubMed ID: 23446755
[TBL] [Abstract][Full Text] [Related]
34. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
Yu C; Krystal G; Varticovksi L; McKinstry R; Rahmani M; Dent P; Grant S
Cancer Res; 2002 Jan; 62(1):188-99. PubMed ID: 11782377
[TBL] [Abstract][Full Text] [Related]
35. The MEK1/2 inhibitor U0126 reverses imatinib resistance through down-regulating activation of Lyn/ERK signaling pathway in imatinib-resistant K562R leukemia cells.
Shi R; Lin J; Guo Y; Gong YP
Pharmazie; 2014 May; 69(5):346-52. PubMed ID: 24855825
[TBL] [Abstract][Full Text] [Related]
36. Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells.
Reddiconto G; Toto C; Palamà I; De Leo S; de Luca E; De Matteis S; Dini L; Passerini CG; Di Renzo N; Maffia M; Coluccia AM
Blood; 2012 Mar; 119(10):2335-45. PubMed ID: 22262776
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of STAT3-interacting protein 1 (STATIP1) promotes STAT3 transcriptional up-regulation and imatinib mesylate resistance in the chronic myeloid leukemia.
Mencalha AL; Corrêa S; Salles D; Du Rocher B; Santiago MF; Abdelhay E
BMC Cancer; 2014 Nov; 14():866. PubMed ID: 25417721
[TBL] [Abstract][Full Text] [Related]
38. Spautin-1, a novel autophagy inhibitor, enhances imatinib-induced apoptosis in chronic myeloid leukemia.
Shao S; Li S; Qin Y; Wang X; Yang Y; Bai H; Zhou L; Zhao C; Wang C
Int J Oncol; 2014 May; 44(5):1661-8. PubMed ID: 24585095
[TBL] [Abstract][Full Text] [Related]
39. Overcoming CML acquired resistance by specific inhibition of Aurora A kinase in the KCL-22 cell model.
Yuan H; Wang Z; Zhang H; Roth M; Bhatia R; Chen WY
Carcinogenesis; 2012 Feb; 33(2):285-93. PubMed ID: 22116466
[TBL] [Abstract][Full Text] [Related]
40. Nuclear translocation of heme oxygenase-1 confers resistance to imatinib in chronic myeloid leukemia cells.
Tibullo D; Barbagallo I; Giallongo C; La Cava P; Parrinello N; Vanella L; Stagno F; Palumbo GA; Li Volti G; Di Raimondo F
Curr Pharm Des; 2013; 19(15):2765-70. PubMed ID: 23092325
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
